Overview

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

Status:
Unknown status

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the role of a FVIII/VWF complex concentrate (Emoclot) in successfully inducing immune tolerance (I.T.I.) in patients with Haemophilia A with inhibitors, including patients at high risk of failure.

Phase:

Phase 4

Details

Lead Sponsor:

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Collaborator:

Sintesi Research Srl

Treatments:

Factor VIII